AbbVie Inc. — ABBV
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $212.08 | $374.65B | 100.5 | 17.5 | 30.0% | 9.8% | $6.56 308.0% | -2039.2 |
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2021-12-31 | $56.2B | $11.5B | $6.53 | N/A | N/A | N/A |
| 1 | 2022-12-31 | $58.1B | $11.8B | $6.69 | 3.3% | 2.5% | 2.5% |
| 2 | 2023-12-31 | $54.3B | $4.9B | $2.75 | -6.4% | -58.9% | -58.8% |
| 3 | 2024-12-31 | $56.3B | $4.3B | $2.40 | 3.7% | -12.0% | -12.8% |
| 4 | TTM 2025-03-31 | $57.4B | $4.2B | $2.34 | 1.8% | -1.9% | -2.5% |
| 5 | Average | 0.6% | -17.6% | -17.9% |
EPS
Forecasts
Y/Y % Change
ABBV Year-over-Year Growth
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 3.3% | -6.4% | 3.7% | 7.5% | 9.1% | 3.4% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 8 | 8 | |
| EPS Growth (%) | 2.5% | -58.9% | -12.0% | 396.8% | 19.2% | 69.5% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 8 | 8 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $56.2B | $8.9B | $8.0B | $12.3B | $8.5B |
| 2022 | $58.1B | $8.9B | $6.5B | $15.3B | $8.5B |
| 2023 | $54.3B | $11.7B | $7.7B | $12.9B | $8.7B |
| 2024 | $56.3B | $8.5B | $12.8B | $14.8B | $8.4B |
| TTM | $58.3B | $8.7B | $13.1B | $14.6B | $8.3B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 3.30 | 0.25 | -19.09 | 23.57 | -0.63 |
| 2023 | -6.44 | 30.96 | 17.90 | -15.65 | 2.73 |
| 2024 | 3.71 | -27.30 | 66.66 | 14.61 | -3.59 |
| TTM | 3.54 | 1.97 | 2.43 | -0.99 | -1.38 |
No unmapped expenses.
Segment Performance
SEGMENTS v2025-09-09 · 2025-09-05 14:55 UTC — Values are shown in a single scale for this table: $B. TTM values are bold. “% of Total (TTM)” shows revenue mix.
| Segment | 2022 Rev ($B) | 2022 OI ($B) | 2023 Rev ($B) | 2023 OI ($B) | 2024 Rev ($B) | 2024 OI ($B) | TTM Rev ($B) | TTM OI ($B) | % of Total (TTM) |
|---|---|---|---|---|---|---|---|---|---|
| Immunology | 57.8B | 0.00B | 52.3B | 0.00B | 53.4B | 0.00B | 53.4B | 0.00B | 51.2% |
| Neuroscience | 13.1B | 0.00B | 15.4B | 0.00B | 18.0B | 0.00B | 18.0B | 0.00B | 17.3% |
| Hematologic Oncology | 12.0B | 0.00B | 10.9B | 0.00B | 12.1B | 0.00B | 12.1B | 0.00B | 11.6% |
| Aesthetics | 10.7B | 0.00B | 10.6B | 0.00B | 10.4B | 0.00B | 10.4B | 0.00B | 9.9% |
| Other Key Products | 6.43B | 0.00B | 6.34B | 0.00B | 5.91B | 0.00B | 5.91B | 0.00B | 5.7% |
| Eye Care | 5.40B | 0.00B | 4.83B | 0.00B | 4.48B | 0.00B | 4.48B | 0.00B | 4.3% |
SEGMENTS v2025-09-09 · 2025-09-05 14:55 UTC — Values are shown in a single scale for this table: $B. TTM values are bold. “% of Total (TTM)” shows revenue mix.
| Segment | 2022 Rev ($B) | 2022 OI ($B) | 2023 Rev ($B) | 2023 OI ($B) | 2024 Rev ($B) | 2024 OI ($B) | TTM Rev ($B) | TTM OI ($B) | % of Total (TTM) |
|---|---|---|---|---|---|---|---|---|---|
| S K Y R I Z I | – | – | – | – | – | – | 9.62B | 0.00B | 238.9% |
| R I N V O Q | – | – | – | – | – | – | 3.64B | 0.00B | 90.5% |
| Other Products | 4.14B | 0.00B | 3.04B | 0.00B | 3.03B | 0.00B | 2.62B | 0.00B | 65.1% |
| Qulipta | – | – | – | – | – | – | 0.95B | 0.00B | 23.6% |
| Botox Therapeutic | – | – | – | – | – | – | 0.69B | 0.00B | 17.2% |
| Vraylar | – | – | – | – | – | – | 0.65B | 0.00B | 16.0% |
| Ubrelvy | – | – | – | – | – | – | 0.50B | 0.00B | 12.5% |
| Vyalev | – | – | – | – | – | – | 0.43B | 0.00B | 10.6% |
| Elahere | – | – | – | – | – | – | 0.35B | 0.00B | 8.8% |
| V E N C L E X T A | – | – | – | – | – | – | 0.32B | 0.00B | 7.9% |
| Creon | – | – | – | – | – | – | 0.13B | 0.00B | 3.3% |
| Epkinly | – | – | – | – | – | – | 0.13B | 0.00B | 3.2% |
| Lumigan Ganfort | – | – | – | – | – | – | 0.03B | 0.00B | 0.7% |
| Other Aesthetics | – | – | – | – | – | – | 0.03B | 0.00B | 0.7% |
| Other Oncology | – | – | – | – | – | – | 0.00B | 0.00B | 0.1% |
| Ozurdex | – | – | – | – | – | – | -0.01B | 0.00B | -0.3% |
| Other Neuroscience | – | – | – | – | – | – | -0.04B | 0.00B | -1.0% |
| Alphagan Combigan | – | – | – | – | – | – | -0.05B | 0.00B | -1.2% |
| M A V Y R E T | – | – | – | – | – | – | -0.06B | 0.00B | -1.5% |
| Linzess Constella | – | – | – | – | – | – | -0.09B | 0.00B | -2.2% |
| Duodopa | – | – | – | – | – | – | -0.10B | 0.00B | -2.5% |
| Other Eye Care | – | – | – | – | – | – | -0.11B | 0.00B | -2.7% |
| Botox Cosmetic | – | – | – | – | – | – | -0.30B | 0.00B | -7.5% |
| Imbruvica | – | – | – | – | – | – | -0.44B | 0.00B | -11.0% |
| Juvederm Collection | – | – | – | – | – | – | -0.46B | 0.00B | -11.5% |
| H U M I R A | – | – | – | – | – | – | -14.4B | 0.00B | -357.7% |
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $136,165M |
| 1 | Cash | $5,175M |
| 2 | Total Liabilities | $134,703M |
| 3 | Total Debt | $69,889M |
| 4 | Total Equity | $1,420M |
| 5 | Debt to Equity Ratio | 49.22 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $185.30 | 4.4% | Nicks Growth: N/A Nick's Expected Margin: N/A FINVIZ Growth: 15% |
Nicks: 6 Finviz: 28 |
Nick's: 0.000 | 5.7 | 79.5 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $2.34 EPS | TTM | $14.96 | -91.9% | $65.52 | -64.6% |
| $12.28 EPS | 2025 | $78.51 | -57.6% | $343.84 | 85.6% |
| $14.06 EPS | 2026 | $89.89 | -51.5% | $393.68 | 112.5% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 28.68% | 9.25% | 28.49% | 9.15% | 1.13% | 0.43% | 30.25% | 9.97% | 96.6% | 98.3% |
| 3 Years | 28.68% | 9.25% | 28.49% | 9.15% | 1.13% | 0.43% | 30.25% | 9.97% | 96.6% | 98.3% |
| 5 Years | 28.68% | 9.25% | 28.49% | 9.15% | 1.13% | 0.43% | 30.25% | 9.97% | 96.6% | 98.3% |
| 10 Years | 28.68% | 9.25% | 28.49% | 9.15% | 1.13% | 0.43% | 30.25% | 9.97% | 96.6% | 98.3% |